Remote jobs at Outlook Therapeutics, Inc.
Enhancing the Treatment of Retinal Disease
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg (U.S.), bevacizumab gamma (E.U.)). LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive U.S. FDA approval and European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany, Austria, and the UK as a treatment for wet AMD.
Mission and direction
Outlook Therapeutics is a commercial-stage biopharmaceutical company dedicated to advancing and commercializing the first ophthalmic formulation of bevacizumab approved for wet age-related macular degeneration. The company focuses on transforming retinal disease care through regulated, science-driven therapies that aim to improve patient access and preserve sight in ophthalmology markets.
Company values
- Patient-centered
- Science-driven
- Compliance-minded
- Collaborative
- Agile
- Mission-led